1
|
Karvinen J, Laitala V, Mäkinen ML, Mulari O, Tamminen J, Hermonen J, Hurskainen P, Hemmilä I. Fluorescence Quenching-Based Assays for Hydrolyzing Enzymes. Application of Time-Resolved Fluorometry in Assays for Caspase, Helicase, and Phosphatase. Anal Chem 2004; 76:1429-36. [PMID: 14987100 DOI: 10.1021/ac030234b] [Citation(s) in RCA: 60] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We have developed assay technologies to measure hydrolyzing enzymes based on homogeneous time-resolved fluorescence quenching (TruPoint). High sensitivity was obtained using fluorescent europium chelates as labels, internally quenched by suitable quenchers and released upon enzymatic reaction. This approach allows robust and sensitive monitoring of low enzyme activities. The assay technology and the choice of donor-acceptor pairs were evaluated in three different enzymatic assays, a protease related to apoptosis, helicase involved in DNA unwinding, and phosphatase having an important role in cellular signaling cascades. All the assays produced an increasing signal, were sensitive, and had a good dynamic range. There were significant differences in optimized quenchers for each of the assays depending on the size, flexibility, and rigidity of the substrates. Also, clear differences in the energy-transfer reactions, their requirements for spectral overlapping, ionic interactions, and energy-transfer distances were found. Each of the enzymatic assays was briefly tested in a high-throughput screening environment by analyzing signal dynamics and statistical relevance as Z' factors.
Collapse
Affiliation(s)
- Jarkko Karvinen
- PerkinElmer Life and Analytical Sciences, Wallac Oy, P.O. Box 10, FIN-20101 Turku, Finland.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Koch U, Biasiol G, Brunetti M, Fattori D, Pallaoro M, Steinkühler C. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization. Biochemistry 2001; 40:631-40. [PMID: 11170379 DOI: 10.1021/bi002160t] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Maturational cleavage of the hepatitis C virus polyprotein involves the viral chymotrypsin-like serine protease NS3. The substrate binding site of this enzyme is unusually flat and featureless. We here show that NS3 has a highly asymmetric charge distribution that is characterized by strong positive potentials in the vicinity of its active site and in the S5/S6 region. Using electrostatic potential calculations, we identified determinants of this positive potential, and the role of six different residues was explored by site-directed mutagenesis. Mutation of residues in the vicinity of the active site led to changes in k(cat) values of a peptide substrate indicating that basic amino acids play a role in the stabilization of the transition state. Charge neutralization in the S5/S6 region increased the K(m) values of peptide substrates in a manner that depended on the presence of negatively charged residues in the P5 and P6 positions. K(i) values of hexapeptide acids spanning P6-P1 (product inhibitors) were affected by charge neutralization in both the active site region and the S5/S6 region. Pre-steady-state kinetic data showed that the electrostatic surface potential is used by this enzyme to enhance collision rates between peptidic ligands and the active site. Calculations of the interaction energies of protease-substrate or protease-inhibitor complexes showed that electrostatic interaction energies oppose the formation of a tightly bound complex due to an unfavorable change in the desolvation energy. We propose that desolvation costs are minimized by avoiding the formation of individual ion pair interactions through the use of clusters of positively charged residues in the generation of local electrostatic potentials.
Collapse
Affiliation(s)
- U Koch
- Istituto di Ricerche di Biologia Molecolare (IRBM) "P. Angeletti", Via Pontina Km 30,600, 00040 Pomezia, Italy
| | | | | | | | | | | |
Collapse
|
3
|
Rusconi S, La Seta Catamancio S, Citterio P, Bulgheroni E, Kurtagic S, Galazzi M, Croce F, Moroni M, Galli M. Virological Response in Multidrug-Experienced HIV-1-Infected Subjects Failing Highly Active Combination Regimens after Shifting from Lamivudine to Didanosine. Antivir Ther 2001. [DOI: 10.1177/135965350100600104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The aim of this study (the RESCUE trial) was to verify the effect of a shift from a lamivudine-containing to a didanosine-containing regimen on viral replication in HIV-1-infected subjects who had experienced prior treatment failure. Sixteen patients (didanosine-experienced in 14/16 cases) were consecutively enrolled: eight patients shifted from lamivudine to didanosine without other changes in their drug regimen. The other eight shifted from lamivudine to didanosine and changed one or more of their other drugs according to their physician's judgement. At the time of the regimen shift, all the subjects exhibited a high-level phenotypic resistance to both zidovudine and lamivudine with changes at codons 70–219 in 100% of cases, at codon 215 in 13 of 16 patients, and the M184V substitution in 13/16 patients. Phenotypic susceptibility to didanosine was maintained in the majority of cases (14/16) despite the high prevalence of changes at codon 184. A statistically significant decrease in viral load ( P<0.005) without a significant increase in CD4 lymphocytes ( P=0.514) was observed after 3 and 6 months from the introduction of the didanosine-containing regimen. These findings suggest the possibility of achieving a viral load response to didanosine-containing regimens in patients with reverse transcriptase (RT) M184V mutations who were previously treated with this drug and its possible use in salvage combinations.
Collapse
Affiliation(s)
| | - Simona La Seta Catamancio
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Paola Citterio
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Elisabetta Bulgheroni
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Semir Kurtagic
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Morena Galazzi
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Francesco Croce
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Mauro Moroni
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| | - Massimo Galli
- Istituto di Malattie Infettive e Tropicali, Università di Milano, Ospedale Luigi Sacco, Milano, Italy
| |
Collapse
|
4
|
Narjes F, Brunetti M, Colarusso S, Gerlach B, Koch U, Biasiol G, Fattori D, De Francesco R, Matassa VG, Steinkühler C. Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease. Biochemistry 2000; 39:1849-61. [PMID: 10677236 DOI: 10.1021/bi9924260] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The replication of the hepatitis C virus (HCV), an important human pathogen, crucially depends on the proteolytic maturation of a large viral polyprotein precursor. The viral nonstructural protein 3 (NS3) harbors a serine protease domain that plays a pivotal role in this process, being responsible for four out of the five cleavage events that occur in the nonstructural region of the HCV polyprotein. We here show that hexapeptide, tetrapeptide, and tripeptide alpha-ketoacids are potent, slow binding inhibitors of this enzyme. Their mechanism of inhibition involves the rapid formation of a noncovalent collision complex in a diffusion-limited, electrostatically driven association reaction followed by a slow isomerization step resulting in a very tight complex. pH dependence experiments point to the protonated catalytic His 57 as an important determinant for formation of the collision complex. K(i) values of the collision complexes vary between 3 nM and 18.5 microM and largely depend on contacts made by the peptide moiety of the inhibitors. Site-directed mutagenesis indicates that Lys 136 selectively participates in stabilization of the tight complex but not of the collision complex. A significant solvent isotope effect on the isomerization rate constant is suggestive of a chemical step being rate limiting for tight complex formation. The potency of these compounds is dominated by their slow dissociation rate constants, leading to complex half-lives of 11-48 h and overall K(i) values between 10 pM and 67 nM. The rate constants describing the formation and the dissociation of the tight complex are relatively independent of the peptide moiety and appear to predominantly reflect the intrinsic chemical reactivity of the ketoacid function.
Collapse
Affiliation(s)
- F Narjes
- Departments of Biochemistry, Medicinal Chemistry, and Computational Chemistry, Istituto di Ricerche di Biologia Molecolare (IRBM) "P. Angeletti", Via Pontina Km 30 600, 00040 Pomezia, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy. J Acquir Immune Defic Syndr 2000. [DOI: 10.1097/00042560-200001010-00004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
6
|
Kuritzkes DR, Shugarts D, Bakhtiari M, Poticha D, Johnson J, Rubin M, Gingeras TR, Kennedy M, Eron JJ. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy. J Acquir Immune Defic Syndr 2000; 23:26-34. [PMID: 10708053 DOI: 10.1097/00126334-200001010-00004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Presence of mutations associated with resistance to zidovudine or lamivudine was determined in isolates of HIV-1 obtained after long-term follow-up of 64 infected individuals who received zidovudine, lamivudine, or both drugs as initial antiretroviral therapy. Zidovudine resistance mutations were less frequent in isolates from patients treated with combination lamivudine plus zidovudine compared with zidovudine alone, but these mutations accumulated over time. Phenotypic resistance to both drugs was found in isolates from 3 of 23 patients. In 3 other patients, lamivudine-resistant virus detected at week 12 was replaced by wild-type virus after longer follow-up, which correlated with a return to baseline levels of plasma HIV-1 RNA. These results show that dual resistance to zidovudine and lamivudine develops over time despite the delayed emergence of zidovudine-resistant mutations. These results also suggest a selective advantage in vivo for HIV-1 species that are wild-type at RT codon 184.
Collapse
Affiliation(s)
- D R Kuritzkes
- University of Colorado Health Sciences Center and Veterans Affairs Medical Center, Denver 80262, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Rusconi S, De Pasquale MP, Milazzo L, Kurtagic S, Bulgheroni E, Citterio P, Galazzi M, La Seta Catamancio S, Galli M. Loss of Lamivudine Resistance in a Zidovudine and Lamivudine Dual-Resistant HIV-1 Isolate after Discontinuation of In Vitro Lamivudine Drug Pressure. Antivir Ther 1998. [DOI: 10.1177/135965359800300407] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We examined the in vitro phenotypic and genotypic profiles of an extensively passaged human immunodeficiency virus type 1 clinical isolate which has been selected for lamivudine resistance, with an M184V mutation in a zidovudine-resistant genetic background, and then cultured with zidovudine alone. Our passaging strategy led to a decrease in lamivudine IC50 values, which were comparable to those prior to lamivudine exposure, and the genotypic restoration of the wild-type sequence at codon 184 of reverse transcriptase.
Collapse
Affiliation(s)
- Stefano Rusconi
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Maria Pia De Pasquale
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Laura Milazzo
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Semir Kurtagic
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Elisabetta Bulgheroni
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Paola Citterio
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Morena Galazzi
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Simona La Seta Catamancio
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| | - Massimo Galli
- Istituto di Malattie Infettive e Tropicali, Universita’ di Milano, Ospedale Luigi Sacco, 20157 Milan, Italy
| |
Collapse
|